Synthesis and three-dimensional qualitative structure selectivity relationship of 3,5-disubstituted-2,4-thiazolidinedione derivatives as COX2 inhibitors

Archives of Pharmacal Research

Volumn 30, Issue 10, 2007, Pages 1186-1204

  Ali, Ahmed M ^a   Saber, Gamal E ^a   Mahfouz, Nadia M ^a   El Gendy, Mahmoud A ^a   Radwan, Awwad A ^a   Hamid, Mohamed A El ^b  

^a Assiut University   (Egypt)

^b African Union Organization St Abbassia   (Egypt)

Author keywords

2,4 thiazolidinediones; 3D QSSR; Catalyst; COX2 inhibitors; Dock6

Indexed keywords

2,4 THIAZOLIDINEDIONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; CARRAGEENAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CHEMICAL STRUCTURE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COMPUTER SIMULATION; DISEASE MODEL; DRUG DESIGN; DRUG EFFECT; EDEMA; ENZYME ACTIVE SITE; HEAT; MOUSE; PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PATHOPHYSIOLOGY; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; REACTION TIME; REPRODUCIBILITY; STOMACH ULCER; SYNTHESIS; THREE DIMENSIONAL IMAGING; X RAY CRYSTALLOGRAPHY;

ANIMALS; CARRAGEENAN; CATALYTIC DOMAIN; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; DRUG DESIGN; EDEMA; HEAT; IMAGING, THREE-DIMENSIONAL; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; REACTION TIME; REPRODUCIBILITY OF RESULTS; STOMACH ULCER; THIAZOLIDINEDIONES;

EID: 35649025795     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02980259     Document Type: Article

References (66)

1. Almansa, C., Alfon, J., de Arriba, A. F., Cavalcanti, F. L., Escamilla, I., Gomez, L. A., Miralles, A., Soliva, R., Bartroli, J., Carceller, E., Merlos, M., and Rafanell, J. G., Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors:1,5-diarylimidazoles. J. Med. Chem., 46, 3463-3475 (2003).
2. Anana, R., Praveen Rao, P. N., Qiao-Hong Chen, Q.-H., and Knaus, E. E., Synthesis and biological evaluation of linear phenylethynylbenzenesulfonamide regioisomers as cyclooxygenase-1/-2 (COX-1/-2) inhibitors. Bioorg. Med. Chem., 14, 5259-5265, (2006).
3. Barnett, J. W., Dunn, J. P., Kertesz, D. J., Miller, A. B., Morgans, J. R., Ramesha, C. S., Sigal, C. E., Sjogren, E. B., Smith, D. B., and Talamas, F. X., Pyrrole derivatives. Eur. Patent, 0714895 (1996).
4. Barnum, D., Greene, J., Smellle, A., and Sprague, P., Identification of common functional configurations among molecules. J. Chem. Inf. Comput Sci., 36, 563-571 (1996).
5. Bender, P. E., Hill, D. T., Offen, P. H., Razgaitis, K. A., Lavanchy, P., Stringer, O. D., Sutton, B. M., Griswold, D. E., DiMartino, M., Walz, D. T., Lantos, I., and Ladd, C. B., Inhibition of the 5-lipoxygenase pathway. J. Med. Chem., 28, 1169-1177 (1985).
6. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., and Bourne, P. E., The Protein Data Bank. Nucleic Acids Research, 28, 235-242 (2000).
7. Bernard, S. D., Arthur, A. D., Patrick, D. J., and Brian, S. E., 6-Benzyl-2H-pyridazin-3-one derivatives, their preparation and their use as inhibitors of prostaglandin G/H synthase I and II (COX I and COX II). Eur. Patent, 0810218 (1997).
8. Black, C., Grimm, E., Leger, S., and Wang, Z., Diaryl-5-Oxygenated-2-(5H) -Furanones As COX-2 Inhibitors. WO Patent, 9636623 (1996b).
9. Black, C., Grimm, E., Leger, S., Prasit, P., and Wang, Z., Diaryl-5-oxygenated-2-(5H)-furanones as COX-2 inhibitors. WO Patent, 9619469 (1996a).
10. Boschelli, D. H., Conner, D. T., Kuipers, P. J., and Wright, C. D., Synthesis and cyclooxygenase and 5-lipoxygenase inhibitory activity of some thiazolidene-4-one analogs of meclofenamic acid. Bioorg. Med. Chem. Lett., 2, 705-708 (1992).
11. Bourassa, D. E., Castaldi, M. J., and Ripin, D. B., Process for preparing heterocyclo-alkysulfonyl pyrazole derivatives. US patent, 0100765 A1 (2003).
12. Bruno, G., Costantino, L., Curinga, C., Maccari, R., Monforte, F., Nicolo, F., Ottana, R., and Vigorita, M. G., Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorg. Med. Chem., 10, 1077-1084, (2002.
13. Buck, J. S. and Ide, W. S., The isomeric desoxybenzanisoins. J. Am. Chem. Soc., 54, 3012-13 (1932).
14. Carabaza, A., Cabré, D., Rotllan, E., Goméz, M., Gutiérrez, M., Garcà, L., and Mauléon, D., A multicentre, randomised, double-blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain. J. Clin. Pharmacol., 36, 505-512, (1996).
15. Cetenko, W. A., Connor, D. T., Sorenson, R. J., Unangst, P. C., and Stabler, S. R., Arylmethylenyl derivatives of thiazolidnones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflamatory agents. Eur. Pat, 0343643, (1989).
16. Dannhardt, G. and Kiefer, W., Cyclooxygenase inhibitors - current status and future prospects. Eur. J. Med. Chem., 36, 109-26, (2001).
17. Dannhardt, G. and Laufer, S., Cyclooxygenase inhibitors - current status and future prospects Curr. Med. Chem., 7,1101-1112 (2000).
18. 3 receptors. J. Chem. Inf. Comput. Sci., 39, 362-369 (1999).
19. De Leval, X., Julemont, F., Delarge, J., Pirotte, B., and Donge, J.-M., New trends in dual 5-LOX/COX inhibition. Curr. Med. Chem., 9, 941-962 (2002).
20. De Lima, J. G., Perrissin, M., Chantegrel, J., Luu-Duc, C., and Narcisse, G., Synthesis and pharmacological evaluation of some 3-phenacyl-5-benzylidene- thiazolidine-2,4-diones. Arzneim-Forsch/Drug Res., 44, 831-834, (1994).
21. Dube, D., Fortin, R., Friesen, R., Wang, Z., and Gauther, J. Y., Substituted pyridines as selective cyclooxygenase-2 inhibitors. US patent, 0065011 (2003).
22. Edvige, G. T., John, K. D., Carol, R. D., and Brian, S. E., Novel Pyrrole derivatives. WO Patent, 9746524, (1997).
23. Fadl, T. A. and Omar, F. A. Paracetamol (acetaminophen) esters of some non-steroidal antiinflammatory carboxylic acids drugs as mutual prodrugs with improved therapeutic index. Inflammopharmacol., 6, 143-157 (1998).
24. Fred, B. and Frederick, G. M., The mechanism of indole formation from phenacylarylamines. Part III. The conditions and mechanism of the isomerisation and indolisation of phenacylarylamines. J. Chem. Soc., 858-870 (1948).
25. Gauthier, J. Y., Leblanc, Y., Black, W. C., Chan, C.-C., Cromlish, W. A., Gordon, R., Kennedey, B. P., Lau, C. K., Leger, S., Wang, Z., Ethier, D., Guay, J., Mancini, J., Riedeau, D., Tagari, P., Vickers, P., Wong, E., Xu, L., and Prasit, P., Synthesis and biological evaluation of 2,3-diarylthiophenes as selective Cox-2 inhibitors-II. Replacing the heterocycle. Bioorg. Med. Chem. Lett., 6, 87-92 (1996).
26. Giles, R. G., Lewis, N. J., Quick, J. K., Sasse, M. J., Urquhart, M. W. J., and Youssef, L., Regiospecific reduction of 5-benzylidene-2,4- thiazolidinediones and 4-oxo-2-thiazolidinethiones using lithium borohydride in pyridine and tetrahydrofuran. Tetrahedron., 56, 4531-4537 (2000).
27. Greene, J., Kahn, S., Savoj, H., Sprague, P., and Teig, S., Chemical Function Queries for 3D Database Search. J. Chem. Inf. Comput. Sci., 34, 1297-1308 (1994).
28. Habeeb, A. G., Praveen Rao P. N., and Knaus, E. E., Design and synthesis of 4,5-Diphenyl-4-Isoxazolines: Novel inhibitors of cyclooxygenase-2 with analgesic and anti-inflammatory activity. J. Med. Chem., 44 2921-2927 (2001).
29. Hashimoto, H., Imamura, K., Haruta J., and Wakitani, K., 4-(4-Cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: Enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522. J. Med. Chem., 45, 1511-1517 (2002).
30. Hernandez-Perez, M., Rabanal, R. M., de La Torre, M. C., and Rodriguez, B., Analgesic, anti-inflammatory, antipyretic and haematological effects of aethiopinone, an o-naphthoquinone diterpenoid from Salvia aethiopis roots and two hemisynthetic derivatives. Planta Med., 61, 505-509 (1995).
31. Hiroshima, A., Pan, C., Kuwano, E., Taniguchi, E., and Eto, M., Three-dimensional pharmacophore hypotheses for the locust neuronal octopamine receptor (OAR3). Part 2: agonists. Bioorg. Med. Chem., 7, 1437-1443, (1999).
32. Kiefer, J. R., Pawlitz, J. L., Moreland, K. T., Stegeman, R. A., Hood, W. F., Gierse, J. K., Stevens, A. M., Goodwin, D. C., Rowlinson, S. W., Marnett, L. J., Stallings, W. C., and Kurumbail, R. G., Structural insights into the stereochemistry of the cyclooxygenase reaction. Nature, 405, 97-101 (2000).
33. Kuntz, I. D., Dock, UCSF Box 2240, UCSF, San Fransico.
34. Kurogi, Y. and Guner, O. F., Pharmacophore modeling and threedimensional database searching for drug design using catalyst. Curr. Med. Chem., 8, 1035-1055 (2001).
35. Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., Gildehaus, D., Miyashiro, J. M., Penning, T. D., Seibert, K., Isakson, P. C., Stallings, W. C., Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature, 384, 644-648, (1996).
36. Lantos, I., Bender, P. E., Razgaitis, K. A., Sutton, B. M., DiMartino, M. J., Griswold, D. E., and Walz, D. T., Anti-inflammatory activity of 5,6-diaryl-2,3-dihydroimidazo[2,1-b]thiazoles. Isomeric 4-pyridyl and 4-substituted-phenyl derivatives. J. Med. Chem., 27 72-75, (1984).
37. Li, C. S., Brideau, C., Chan, C. C., Savoie, C., Claveau, D., Charleson, S., Gordon, R., Greig, G., Gauthier, J. Y., Lau, C. K., Riendeau, D., Therien, M., Wong, E., and Pasit, P., Pyridazinones as selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett., 13, 597-600 (2003).
38. Lo, C. P. and Shropshire, E. Y., Notes - Alkylation of 2,4-Thiazolidinedione. J. Org. Chem., 22, 999-1001 (1957).
39. Lo, C. P., Shropshire, E. Y., and Croxall, W. J., 5-Aralylidine-3- isobutyl-2,4-thiazolidinediones. J. Am. Chem. Soc., 75, 4845-4846 (1953).
40. Lohray, B. B., Bhushan, V., Reddy, A. S., Rao, P. B., Reddy, N. J., Harikishore, P., Haritha, N., Vikramadityan, P. K., Chakrabarti, R., Rajagopalan, R., and Katneni, K., Novel euglycemic and hypolipidemic agents. 4. pyridyl- and quinolinyl-containing thiazolidinediones. J. Med. Chem., 42, 2569-81 (1999).
41. Lombardino, J. G., Non-Steroidal Anti-Inflammatory Drugs, Wiley, New York, pp. 255-431 (1985).
42. Naser, M. N. A. and Said, S. A., Novel 3, 3a, 4, 5, 6, 7-hexahydroindazole and arylthiazolylpyrazoline derivatives as anti-inflammatory agents. Arch. Pharm. Pharm. Med. Chem., 336, 551-559 (2003).
43. Nojima, H., Tsuneki, H., Kimura, I., and Kimura, M., Accelerated desensitization of nicotinic receptor channels and its dependence on extracellular calcium in isolated skeletal muscles of streptozotocin-diabetic mice. Br. J. Pharmacol., 116, 1680-1684 (1995).
44. Omar, F. A., Mahfouz, N. M., and Fadl, T. A., Design, synthesis and anti-inflammatory activity of some 1,3,4-oxadiazole derivatives. Eur. J. Med. Chem., 31, 819-825 (1996).
45. Pal, M., Madan, M., Padakanti, S., Pattabiraman, V. R., Kalleda, S., Vanguri, A., Mullangi, R., Rao Mamidi, N. V. S., Casturi, S. R., Malde, A., Gopalakrishnan, B., and Yeleswarapu, K. R., Synthesis and cyclooxygenase-2 inhibiting property of 1,5-diarylpyrazoles with substituted benzenesulfonamide moiety as pharmacophore: preparation of sodium salt for injectable formulation. J. Med. Chem., 46, 3975-3984 (2003).
46. Palomer, A., Cabre, F., Pascual, J., Campos, J.,. Trujillo, M. A, Entrena, A., Gallo, M. A., Garcia, L., Mauleon, D., and Esponosa, A., Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models. J. Med. Chem., 45, 1402-1411 (2002).
47. Picot, D., Loll, P. J., and Garavito, R. M., The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature, 367, 243-249 (1994).
48. Poitevin, B., Tordjman, C., Pastoureau, P., Bonnet, J., and De Nanteuil, G., 1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole Derivatives: A new series of potent and selective COX-2 inhibitors in which a sulfonyl group is not a structural requisite. J. Med. Chem., 43, 4582-4593 (2000).
49. Reddy, M. V. and Bell, S. C., Processes for the preparation of substituted isoxazoles and 2-isoxazolines. US Patent, 0162813 A1 (2003).
50. Rosales, C. A., Gonzalez, C. G., and Barreda, M. C. T., Novel imidazole derivatives with anti-inflammatory activity. US patent, 0176481 A1 (2003).
51. Rowlinson, S. W., Kiefer, J. R., Prusakiewicz, J. J., Pawlitz, J. L., Kozak, K. R., Kalgutkar, A. S., Stallings, W. C., Kurumbail, R. G., and Marnett, L. J., A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J. Biol. Chem., 278, 45763-45769 (2003).
52. Sakya, S. M. and Rast, B., Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents. US patent, 0119836 A1 (2003).
53. Sakya, S. M., Shavnya A., and Rast, B., Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents. US patent, 0125368 A1 (2003a).
54. Sakya, S. M., Shavnya A., and Rast, B., Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents. US patent, 0119835 A1 (2003b).
55. Seehra, J. S., Xiang, Y., Bemis, J. E., McKew, J., Kaila, N., and Chen, L., Inhibitors of phospholipase A2. WO Patent, 9943672 (1999a).
56. Seehra, J. S., McKew, J., Lovering, F., Bemis, J. E, Xiang, Y., Chen, L., and Knopf, J. L., Inhibitors ofphospholipas enzymes. WO Patent, 9943654 (1999b).
57. Shevchuk, M. I. and Dombrovskii, A. V., Preparation of α-monobromomethyl aryl ketones by bromination of methyl aryl ketones in dioxane. Zhur. Obshch. Khim. 1963, 33, 1135-1136; through Chem. Abstr., 59, 9921g (1963).
58. Sui, Z., Guan, J., Ferro, M. P., McCoy, K., Wachter, M. P., Murray, W. V., Singer, M., Steber, M., Ritchie, D. M., and Argentieri, D. C., 1,3-Diarylcycloalkanopyrazoles and diphenyl hydrazides as selective inhibitors of cyclooxygenase-2. Bioorg. Med. Chem. Lett., 10, 601-604 (2000).
59. Talley, J. J., Brown, D. L., Nagarajan, S., Carter, J. S., Weier, R. M., Stealey, R. M., Collins, P. W., Roland, R. D., and Karen, S., Substituted isoxazoles for the treatment of inflammation. US patent, 5633272 (1997).
60. Turkevich, N. M., Vvedenskii, V. M., and Petlich-naya, L. M., Substitution in the azolidine rign. Method of obtaining pseudothiohydantoin and 2,4-thiazolidinedione. Ukr. Khim. Zh, 1961, 27, 680-81; through Chem. Abstr., 56, 14254e (1962).
61. Unangst, P. C., Conner, D. T., Cetenko, W. A., Sorenson, R. J., Kostlan, C. R., Sircar, J. C., Wright, C. D., Schrier, D. J., and Dyer, R. D., Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl] methylene]oxazoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity. J. Med. Chem., 37, 322-28 (1994).
62. Vachal, P., Pihera, P., and Svoboda, J., Thieno[3,2-b]benzofuran - Synthesis and Reactions. Collect. Czech. Chem. Commun., 62, 1468 (1997).
63. Valencia, E., Feria, M., Diaz, J. G., Gonzalez, A., and Bermejo, J., Antinociceptive, anti-inflammatory and antipyretic effects of lapidin, a bicyclic sesqiterpene. Planta Med., 60, 395-99 (1994).
64. Vane, J. R., Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature-New biology, 231, 232-/235 (1971).
65. Velázquez, C., Praveen Rao, P. ,N., McDonald, R., and Knaus, E. E., Synthesis and biological evaluation of 3,4-diphenyl-1,2,5-oxadiazole-2- oxides and 3,4-diphenyl-1,2,5-oxadiazoles as potential hybrid COX-2 inhibitor/nitric oxide donor agents. Bioorg. Med. Chem., 13, 2749-57 (2005).
66. Ward, A. M., Investigations on the bivalency of carbon. Part II. The displacement of chlorine from desyl chloride. Benzoin diethylacetal. J. Chem. Soc., 1541-1553 (1929).